Pimozidum [INN-Latin]

Pimozidum [INN-Latin] Brand names, Pimozidum [INN-Latin] Analogs

Pimozidum [INN-Latin] Brand Names Mixture

No information avaliable

Pimozidum [INN-Latin] Chemical_Formula

C₂₈H₂₉F₂N₃O

Pimozidum [INN-Latin] RX_link

http://www.rxlist.com/cgi/generic3/orap.htm

Pimozidum [INN-Latin] fda sheet

Pimozidum [INN-Latin] msds (material safety sheet)

Pimozidum_[INN-Latin] MSDS

Pimozidum [INN-Latin] Synthesis Reference

No information avaliable

Pimozidum [INN-Latin] Molecular Weight

461.546 g/mol

Pimozidum [INN-Latin] Melting Point

214-218 ^oC

Pimozidum [INN-Latin] H₂O Solubility

10 mg/L

Pimozidum [INN-Latin] State

Solid

Pimozidum [INN-Latin] LogP

5.761

Pimozidum [INN-Latin] Dosage Forms

Tablet

Pimozidum [INN-Latin] Indication

Used for the suppression of motor and phonic tics in patients with Tourette's Disorder who have failed to respond satisfactorily to standard treatment.

Pimozidum [INN-Latin] Pharmacology

Pimozide is an orally active antipsychotic drug product which shares with other antipsychotics the ability to blockade dopaminergic receptors on neurons in the central nervous system. However, receptor blockade is often accompanied by a series of secondary alterations in central dopamine metabolism and function which may contribute to both pimozide's therapeutic and untoward effects. In addition, pimozide, in common with other antipsychotic drugs, has various effects on other central nervous system receptor systems which are not fully characterized. Pimozide also has less potential for inducing sedation and hypotension as it has more specific dopamine receptor blocking activity than other neuroleptic agents (and is therefore a suitable alternative to haloperidol).

Pimozidum [INN-Latin] Absorption

Greater than 50% absorption after oral administration. Serum peak appears 6-8 hours post ingestion.

Pimozidum [INN-Latin] side effects and Toxicity

LD₅₀ = 1100 mg/kg (rat, oral), 228 mg/kg (mouse, oral)

Pimozidum [INN-Latin] Patient Information